

# Window of opportunity clinical trial

Window of opportunity trials allow a drug (or other intervention) of interest to be given to a patient over a short period of time, usually 2--4 weeks, prior to the instigation of standard therapy.

[Window of opportunity clinical trial](#) designs can provide early insight into the biological plausibility of a novel therapeutic [strategy](#) in the clinical setting. A variety of window-of-opportunity trial designs, which take into account the limited access to treated [tissue](#) and the challenges with obtaining pretreatment control tissues, have been used for the initial development of traditional and targeted small-molecule [drugs](#) and biologic therapies, including immunotherapies and oncolytic viral therapies. Early-stage development of [glioma treatment](#) should include a window-of-opportunity component whenever feasible <sup>1)</sup>.

<sup>1)</sup>

Vogelbaum MA, Li G, Heimberger AB, Lang FF, Fueyo J, Gomez-Manzano C, Sanai N. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. *Am Soc Clin Oncol Educ Book*. 2022 Apr;42:1-8. doi: 10.1200/EDBK\_349175. PMID: 35580289.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

[https://neurosurgerywiki.com/wiki/doku.php?id=window\\_of\\_opportunity\\_clinical\\_trial](https://neurosurgerywiki.com/wiki/doku.php?id=window_of_opportunity_clinical_trial)

Last update: **2024/06/07 02:52**

